Elitek

Product manufactured by Sanofi-Aventis U.s. Llc

Application Nr Approved Date Route Status External Links
BLA103946 None None None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Elitek Is Indicated For The Initial Management Of Plasma Uric Acid Levels In Pediatric And Adult Patients With Leukemia, Lymphoma, And Solid Tumor Malignancies Who Are Receiving Anticancer Therapy Expected To Result In Tumor Lysis And Subsequent Elevation Of Plasma Uric Acid. Elitek Is A Recombinant Urate-Oxidase Indicated For Initial Management Of Plasma Uric Acid Levels In Pediatric And Adult Patients With Leukemia, Lymphoma, And Solid Tumor Malignancies Who Are Receiving Anticancer Therapy Expected To Result In Tumor Lysis And Subsequent Elevation Of Plasma Uric Acid. ( 1 ) Limitations Of Use: Elitek Is Indicated Only For A Single Course Of Treatment. ( 1 ) Limitations Of Use Elitek Is Indicated Only For A Single Course Of Treatment [See Warnings And Precautions (5.1) ] .

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Rasburicase

Comments